Mutation detail:
| Mutation site | N501Y |
| Virus | SARS-CoV-2 |
Mutation level  |
Amino acid level |
| Gene/protein/region type | S |
| Gene ID | 43740568 |
| Country | USA |
| Mutation type |
nonsynonymous mutation |
| Genotype/subtype/clade | - |
| Sample |
Human |
| Variants | Alpha/Beta/Gamma |
| Viral reference sequence | |
| Drug/antibody/vaccine | - |
| Transmissibility |
- |
| Transmission mechanism | - |
| Pathogenicity |
- |
| Pathogenicity mechanism | - |
| Immune escape mutation | - |
| Immune escape mechanism | - |
| RT-PCR primers probes | - |
Protein detail:
| Protein name | Spike glycoprotein |
| Uniprot protein ID | P0DTC2 |
| Protein length | 1273 amino acids |
| Protein description | Spike protein is one of the structural proteins of SARS-CoV-2. The monomeric protein consists of one large ectodomain, a single-pass transmembrane anchor, and a short intracellular tail at C-terminus. It encompasses 22 glycosylation sites. S protein cleaves into two subunits namely S1 and S2 following receptor recognition. Receptor Binding Domain (RBD) in S1 subunit plays a major role in ACE2 receptor binding. |
Literature information:
| Pubmed ID | 34425281 |
| Clinical information | No |
| Disease | - |
| Published year | 2021 |
| Journal | Biochem Biophys Res Commun. |
| Title | Mutation-induced changes in the receptor-binding interface of the SARS-CoV-2 Delta variant B.1.617.2 and implications for immune evasion |
| Author | Prabin Baral, Nisha Bhattarai, Md Lokman Hossen, |
| Evidence | The RBD of the spike protein has mutations N501Y in B.1.1.7, K417N/E484K/N501Y in B.1.351, and L452 R/T478K in Delta B.1.617.2.The RBD mutations in or around the interfacial region can directly impact the RBD's ability to bind ACE2 or neutralizing antibodies. |